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SUMMARY

Author Manuscript

We present a systems strategy that facilitated the development of a molecular signature for
glioblastoma (GBM), composed of 33 cell-surface transmembrane proteins. This molecular
signature, GBMSig was developed through the integration of cell-surface proteomics and
transcriptomics from patient tumors in the REMBRANDT (n=228) and TCGA datasets (n=547)
and can separate GBM patients from controls with an MCC value of 0.87 in a lock-down-test.
Functionally, 17/33 GBMSig proteins are associated with TGFβ signaling pathways, including:
CD47, SLC16A1, HMOX1 and MRC2. Knockdown of these genes impaired GBM invasion,
reflecting their role in disease-perturbed changes in GBM. ELISA assays for a subset of GBMSig
(CD44, VCAM1, HMOX1, and BIGH3) on 84 plasma specimens from multiple clinical sites
revealed a high degree of separation of GBM patients from healthy controls (AUC 0.98 in ROC).
Additionally, a classifier based on these four proteins differentiated the blood of pre- and posttumor resections, demonstrating potential clinical value as biomarkers.

eTOC Blurb
Multidimensional analysis of GBM cell-surface proteins reveals a disrupted membrane-signaling
network that can be identified from the blood of GBM patients, a subset of which can distinguish
between normal and diseased individuals.
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INTRODUCTION

Author Manuscript

A systems approach that integrates multi-omic measurements offers an avenue for better
understanding the emergent properties and complexities of a disease process. Considering
the recent advancements in omics technologies and machine learning, the power of a
systems approach, in contrast to the single parameter atomistic approach, can enable the
development of molecular signatures for complex diseases such as cancer (Sung et al.,
2012). However, such an approach that integrates data types across multiple sources also
needs empirical validation since the separation of true disease signal from noise that arises
out of variability in omics platforms-both biological and technical is essential. Here we have
attempted to develop such a molecular signature for glioblastoma (GBM) through the
integration of high-resolution proteomics and transcriptomics supported by end-to-end
experimental validation.

Author Manuscript

Despite significant improvements in treatment and survival outcomes for other cancers, the
median survival rate for GBM with treatment is still only 15 months—a figure that has been
largely unchanged for decades (Demuth T, 2004; Mrugala, 2013; Delyon et al., 2015;
Grabowski and Sehouli, 2015; Jorgensen and Knudtson, 2015; Limani et al., 2015; Milroy,
2015; Rollig et al., 2015). MRI scans are used to diagnose or evaluate tumor progression, but
these studies are often difficult to interpret due to variability in the appearance of the tumor
and include a degree of subjectivity (Thompson et al., 2011). The field of neurooncology
would benefit from a blood-based molecular signature of GBM that could complement MRI
scans and existing genomic tests (Hegi and Stupp, 2013; Kurscheid et al., 2015; Murat et al.,
2008; Stupp et al., 2006).
Most attempts at developing robust biomarkers have failed to make it to the clinic (Omenn et
al., 2012; Sung et al., 2012), and there is a process of validation that must be followed to
generate a robust molecular signature appropriate for clinical use. That is not what we will
present herein – that will be a subsequent downstream evaluation. Rather, here we have
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focused on the development of a molecular signature, GBMSig, which defines the set of
transmembrane proteins whose transcript concentrations are perturbed in GBMs compared
to healthy control tissues and on identifying the extent to which some of these have been
released into the blood and can be observed by targeted mass spectrometry.

Author Manuscript

Cell-surface transmembrane proteins occupy a strategic location between the cell and its
microenvironment, and can propagate signals from both exofacial and cytoplasmic ends of
the membrane (Chen et al., 2008; De Marco et al., 2013; Kandouz, 2012; Murai and
Pasquale, 2010; Pasquale, 2010). Since aberrant expression of these proteins on the cellsurface is known to disrupt normal cell activities and influence neoplastic transformation
(Okumura et al., 2004; Teh and Chen, 2012), we hypothesized that integration of
transcriptomic and proteomic expression data for these proteins would enrich for putative
targets that could be the basis for a molecular GBM signature with a higher probability of
being mechanistically linked to the underlying pathology. Cell-surface transmembrane
proteins are often cleaved and shed into the blood in pathological conditions, making them
ideal targets for diagnostic blood markers (Li et al., 2013; Shao et al., 2012; Varady et al.,
2013).

Author Manuscript

Cell-surface-transmembrane proteins tend to be low-abundant in the blood and are the
proverbial needles in the haystack, presenting significant challenges in their detection even
after depletion of highly abundant proteins. Reproducible quantification of these low
abundant proteins can only be achieved after they have been identified. To first identify
candidate tumor-derived, cell-surface transmembrane proteins, we performed comparative
cell-surface proteomics analyses of four relevant GBM cell lines: CD133+ cancer stem cells,
healthy neural stem cells, as well as the GBM cell lines U87MG and T98. Considering the
possibility that the protein expression profile could be altered for a variety of reasons,
including in-vitro culturing (Ertel et al., 2006; Vogel et al., 2005), we integrated cell-surface
proteomics data with primary GBM tissue transcriptomic compendia of the REMBRANDT
and TCGA. This integrative approach (Figure 1) helped us to verify mRNA expression of
corresponding proteins identified through shotgun proteomics and also to develop a robust,
GBM-specific membrane signature (GBMSig) composed of 33 proteins that reflects the
biology of GBM with potential for tissue and blood-based diagnosis.

RESULTS
Compositional analysis of GBM cell-surface proteome by shotgun proteomics

Author Manuscript

There is significant heterogeneity across tumors of individuals, even within each of the four
molecular subtypes. To capture some of this heterogeneity, we performed cell-surface
proteomics on four cell lines including two GBM cell lines UMG87 and T98, a GBM cancer
stem cell line (grown at the source, Celprogen, that ensured CD133 expression) and a
healthy neural stem cell line (positive for putative stem cell markers tub iii, oct-4, sox-2, and
nestin from Millipore). Cell-surface proteins were labeled and captured with membraneimpermeable sulfo-NHS-SS-biotin from intact cells (Figure S1).
Captured cell-surface proteins were subjected to high-resolution mass spectrometry in
triplicate (technical replicates) and the proteins were identified using the Global Proteome
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Machine [(the GPM) (http://www.theGPM.org)] with minimum log expectation scores of
<10−3 (Craig and Beavis, 2003, 2004; Fenyo et al., 2007; Ghosh et al., 2010). We identified
a total of 868, 813, 541, and 564 non-redundant proteins from U87MG, T98, neural stem
cell, and cancer stem cell populations, respectively (Figure 2A–D and Table S1). While our
experimental approach was designed to enrich for cell-surface proteins, we also employed
the transmembrane prediction algorithm TMHMM (Krogh et al., 2001; Moller et al., 2001)
to identify those cell-surface proteins with transmembrane domains from the total identified
proteins. Although this filtering step was rather strict and likely eliminated several true
positives, we were left with 157, 154, 98, and 80 cell-surface transmembrane proteins in
U87MG, T98, neural stem cell, and cancer stem cell lines, respectively. Overall 274 different
cell-surface transmembrane proteins were identified from all four cell lines. Among cellsurface transmembrane proteins identified, we found 53 cluster-of-differentiation (CD)
markers, which in general offer an immunological basis for separating different cell types
(Beare et al., 2008; Erber, 1990).

Author Manuscript

We also identified 98 multi-transmembrane domain containing cell-surface proteins, which
are underrepresented in whole-cell proteomic datasets because of their hydrophobicity and
limited cellular abundance. As would be expected, functional classification of these proteins
highlighted the enrichment of those biological processes that are known to be associated
with cell-surface activities such as cell adhesion and migration, transport, and bi-directional
signaling (Figure 2E–F). We also observed a difference in enrichment of immune regulatory
processes among all three distinct cancer cell lines (U87MG, T98, and cancer stem cell line)
compared to the healthy neural stem cells—reflective of the functional differences between
these cell types (Table S1). Our cell-surface proteome analysis identified transmembrane
proteins expressed among various GBM cell lines related to different aspects of GBM
biology. This approach provided us with a list of proteomic targets that, upon further
selection based on RNA expression (described below), were good candidates for detection
and measurement by quantitative selected reaction monitoring (SRM) mass spectrometry.
The XML data files are available for viewing at http://human.thegpm.org/tandem/
thegpm_upview.html. Unique Global Proteome Machine IDs for proteins identified in each
cell line are provided in the key resources table of STAR Method section of this paper.
Differentially expressed cell-surface transmembrane proteins in GBM

Author Manuscript

For a candidate list of differentially expressed transcripts between tumor and non-tumor
regions of the brain, we utilized microarray data from the REMBRANDT tissue source
(http://rembrandt.nci.nih.gov). Out of 274 cell-surface transmembrane proteins identified
from the proteomics study, we found expression data for 202 (532 independent probes)
corresponding transcripts in REMBRANDT. Expression levels in the tumor transcriptomes
were, on average, much more abundant than those from their normal counterparts, possibly
as an artifact of the small number of available normal control samples, but also likely due to
a real difference in transcript expression. Because of the small number of control samples,
we used a conservative cutoff of two-fold average expression change with FDR<0.05.
Among the resulting 202 selected transcripts, we observed 155 of them were upregulated
and 47 were down-regulated (Figure 3A). To identify GBM-specific cell-surface
transmembrane protein expression changes, we filtered out transcripts found to be
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differentially expressed in non-GBM brain diseases such as astrocytoma (N=148 tumors)
and oligodendroma (N=67 tumors) relative to the same REMBRANDT control samples.
This filtering approach further reduced the number of candidate cell-surface transmembrane
proteins from 202 to 33 (Figure 3A–F and Figure S2).

Author Manuscript

To increase confidence that these 33 candidate proteins could represent real differences
between case and control samples, we tested their performance as a GBM signature
(designated as GBMSig) in an independent dataset: TCGA (The Cancer Genome Atlas,
2008) (N=547 GBM tumor samples and 10 healthy brain tissues). We designed a Support
Vector Machine (SVM) classifier (C. Cortes and Vapnik, 1995) with parameters tuned in 10fold cross validation on the REMBRADT training set (Figure S2A). We then classified the
TCGA test set with a lock-down test (Figure S2B). We obtained a Mathew’s correlation
coefficient (MCC) of 0.87, exhibiting 99% positive predictive value and 89% negative
predictive value for our classifier. Of note, while the high predictive values for both
REMBRANDT and TCGA should be evaluated in the light of the disproportionately small
control samples, the purpose of this step was to evaluate the robustness of the targets
following integration of the proteomic and transcriptomic datasets and thus this
transcriptomic step was a means for helping to select the protein signature (GBMSig)
presented herein and not an end in and of itself.

Author Manuscript

Principal component analysis (PCA) of the GBMSig genes and individual specificities and
sensitivities from ROC analyses of training and validation set (TCGA) are presented in
Figures 3C–3F and Table S2 respectively. Taken together, these results support the predictive
power of the 33 protein GBMSig classifier and suggest that the integration of both
proteomic and transcriptomic data and stringent filtering have enriched for candidate
proteins of interest that might be quantitatively different in their expression between GBM
and control patients.
Quantitative SRM assays for GBMSig

Author Manuscript

As an initial step to evaluating a subset of GBMSig as biomarkers in the blood, we
developed quantitative SRM assays for all 33 proteins (Li et al., 2013; Picotti and Aebersold,
2012;Bereman et al., 2012). Our earlier cell-surface protein profiling of GBM cell lines
provided data for selecting mass spectrometry compatible peptides with appropriate mass to
charge ratios (m/z). Seventy cell-surface protein peptide representatives from 33 GBMSig
proteins were generated for SRM assay development—approximately 2 for each protein.
Synthetic peptides labeled (13C15N) C-terminally with either lysine (K) or arginine (R) act
as surrogates of endogenous peptides. These peptides were subjected to collision energy
(CE) optimization (Maclean et al., 2010) to maximize the release of trapped energy from
each peptide bond. Three parental (Q1) charges (+2, +3, and +4) and two daughter (Q3) ion
charges (+1 and +2) of peptides were tested in all feasible combinations for assay
optimization; the Q1/Q3 transition-CE combination that demonstrated the highest SRM
peak-intensity and was minimally affected by interfering ions was selected for assay
validation (Table S3). In the final SRM assay, the best performing peptide with a minimum
of three transitions was used for quantitation. Retention time of each surrogate peptide was
determined empirically, which helped to develop dynamic-SRM assays (d-SRM). This
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targeted approach improved the sensitivity and specificity, enabling the reproducible
measurement of low abundant GBMSig proteins in complex bio-specimens. Four resected
GBM tumors and two non-tumor brain tissue samples were homogenized, enzymatically
digested, clarified using C18, and spiked with synthetic C-terminally labeled (13C15N K/R)
peptides for subsequent SRM mass spectrometry analysis (three technical replicates). Of the
33 GBMSig proteins assayed we were able to reliably detect 21 across all samples. Twelve
of the 21 GBMSig proteins were overexpressed in all four GBM tissues relative to nontumor brain tissues. The list of these proteins including nine proteins with p<0.05 are
presented in Table S4. Protein expression data and PCA analyses are represented in Figure
4A–C. Although a majority of GBMSig proteins (12 of 21) revealed differential expression
between tumor and non-tumor regions of the brain, intratumor heterogeneities in GBMSig
expression as investigated through tumor subtyping (Phillips et al., 2006) underscored the
nature of combinatorial perturbation of membrane networks across different clinical
specimens (Figure 4D, Table-S4–5).
Utility of GBMSig in the assessment of tumor progression and diagnosis through blood
analysis

Author Manuscript

Cell-surface proteins are known to be secreted or shed into the blood stream by both healthy
and tumor cells and the concentration changes in those proteins from tumor cells (as
compared to normal cells) reflect the fact that their cognate networks have become perturbed
(Li et al., 2013; Shao et al., 2012). As would be expected, given our initial decision to select
for cell-surface proteins, we found twenty-one of 33 GBMSig proteins to possess N-terminal
secretion signal sequences (SignalP4.1, www.cbs.dtu.dk). However, protein secretion in the
blood is a complex process and can be controlled by a multitude of factors (Uhlen et al.,
2015). Therefore, we sought to identify which GBMSig proteins could be identified in the
blood of GBM patients through empirical means. In a pilot study, we evaluated four GBM
plasmas (pre-operative blood collection) for circulating GBMSig proteins by SRM mass
spectrometry (Table S6). Following immunodepletion of the 14 most abundant blood
proteins, we detected 14 of 33 GBMSig proteins independently in triplicate SRM runs
(Table S6). Four circulating GBMSig proteins (HMOX1, CD44, VCAM1, and BIGH3
(TGFBI)) were selected for further evaluation by ELISA assays for potential GBM diagnosis
based on 1) detection by SRM in the blood of GBM patients; 2) high AUC values (>0.95) in
ROC analyses of REMBRANDT and TCGA transcriptomic datasets; and 3) the availability
of off-the shelf ELISA kits.

Author Manuscript

We assembled a collection of 84 plasma specimens from five different sources and subjected
them to ELISA analyses for the four selected proteins. As we were unable to obtain GBM
and normal plasma samples from the same source (and same collection procedure), we
obtained each from multiple locations to help mitigate batch effects by performing analyses
across data from multiple distinct sample sources, and different sources entirely in the
training and test sets. All samples obtained were collected using the standard collection
protocol for K2-EDTA (purple cap) blood. We subjected the samples to an independent
training and validation format with each set being composed of age and gender matched
GBM samples (21 training, 21 validation) and healthy samples (21 training, 21 validation)
(Figures 5A–C and S3, Table S7). Following batch-normalization (standard score), the

Cell Syst. Author manuscript; available in PMC 2018 May 24.

Ghosh et al.

Page 7

Author Manuscript

training set was modeled using linear discriminant analysis (LDA). LDA characterizes 2
classes as Gaussian densities of equal covariance using a linear combination of features. The
performance of four GBMSig proteins in the identification of GBM class was assessed for
validation set after locking down parameters. We observed 95.2% sensitivity and 95.2%
specificity for the independent validation set (GBM=21, Healthy=21). ROC analyses of the
training set exhibited an AUC of 0.99 while the validation set presented an AUC of 0.98
(Figure 5A–C), highlighting significant differences in the abundance of these proteins in
GBM patients versus normal controls. Power analysis of ELISA results also indicated good
agreement between the effect size (>|0.6|) and the sampling method (power>0.8) (Figure
S3E).

Author Manuscript

We then examined the changes in blood concentrations of the same four proteins (HMOX1,
CD44, VCAM1, and BIGH3) for ten GBM patients prior to and after tumor resection. Blood
samples were collected preoperatively and postoperatively at 24 hrs, 48 hrs, and ~10 days
post-surgery (first post-operative visit). From ELISA analysis, we observed significant
changes (p<0.05; ROC AUC of 0.83) in the blood concentrations of three proteins (HMOX1,
CD44, and BIGH3), possibly reflecting the pathophysiological changes related to tumor
resection (Figure 5D–E) within ten days of surgery. PCA analysis also revealed a separation
of 52.1% on PC1 and 27% on PC2 for changes in the blood concentrations of HMOX1,
CD44, and BIGH3 between 24hrs and 10days post-resection (Figure S4A–B, Table S8).
However, since there was no endpoint to this study, it was not possible to relate the changes
in the blood concentrations of these GBMSig proteins to the overall survival (OS) or
progression-free-survival (PFS) of patients, which could be evaluated in future by
undertaking longer and more frequent post-operative follow-ups.

Author Manuscript

Connections between the classifier and TGF-β responsiveness

Author Manuscript

Pathway analysis of GBMSig proteins using the KEGG database (Kanehisa and Goto, 2000)
and GeneMANIA (www.genemania.org) reflected the role of GBMSig proteins in several
established aspects of GBM biology, including: focal adhesion, ECM-receptor interaction,
apoptosis, and the MAPK signaling pathway (Figures 2F and S2C). Additionally, coexpression analysis of GBM tissue transcriptomics and proteomics data (Figure 3A,4A,4C)
indicated that a number of proteins within the GBMSig classifier co-expressed with TGFBI
(BIGH3)—a known TGF-β-inducible protein (Lauden et al., 2014; Nummela et al., 2012).
This observation, along with a known role for TGF-β in cancer and GBM (Pickup et al.,
2013), highlighted possible TGF-β1 responsive network components operating within
GBMSig classifier that could impact the modulation of other GBMSig proteins within the
classifier. To determine whether GBMSig proteins could respond to TGF-β treatment and
provide biological, mechanistic evidence for the classifier, we tested TGF-β1 responsiveness
in the astrocytoma cell line U87MG through induction of C-terminal phosphorylation of
SMAD2 (Figure 6A). Conversely, SMAD2 phosphorylation is diminished in the presence of
TGF-β-inhibitor (SB 431542). Cell viability did not significantly change following
treatment with TGF-β1 or its inhibitor relative to untreated cells (data not shown). Proteomic
changes of GBMSig expressions following TGF-β/inhibitor treatment were evaluated by
SRM assays. We observed 13 GBMSig proteins including TGFBI (BIGH3), which exhibited
at least 1.5 fold higher expression following TGF-β treatment relative to cells treated with
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TGF-β-inhibitor alone (Figure 6B and Table-S10). As basal TGF- β expression could
contribute to expression of our GBMSig proteins, we found that cells pretreated with TGFβ-inhibitor and subsequent TGF-β treatment modulated the expression of GBMSig proteins.
There were four additional GBMSig proteins (CD47, MYOF, ABCA1, and CD44) that
exhibited a positive enrichment (>1.2 fold over inhibitor treatment) for TGF-β treatment in
comparison to TGF-β-inhibitor treatment alone. Details are presented in Table S10 and
Figure S5. Changes in protein expression of SLC16A1, MRC2, SLC16A3, CD47, and CD97
after TGFβ treatment relative to inhibitor treatment were confirmed by alternate method
flow cytometry (Figure 6C). Results were consistent with the changes in protein expression
observed by SRM. These observations highlight the modular responsiveness of a subset of
GBMSig classifier with TGF-β signaling that was previously undescribed (Figure 6D).
TGF-β1 responsive GBMSig subset and tumor invasion

Author Manuscript
Author Manuscript

As a known inducer of epithelial to mesenchymal transition (EMT), TGF-β1 plays an
important role in the local metastasis of tumor cells (Picon et al., 1998, Hoelzinger et al.,
2007). We determined if overexpression of TGFβ1-responsive transcripts from our GBMSig
subset correlated with patient survival in the REMBRANDT data. Co-expression of these
genes indeed correlated with poor patient survival (p<0.003, Log Rank, Mantel-Cox) (Figure
6G). This correlation could be the result of several factors related to tumor development
concurrent with the hypothesis that invasion is, in part, attributable to the action of TGF-β1.
To further investigate the role of our TGF-β targets in this context, we inhibited the
expressions of SLC16A1, MRC2, and CD47 through siRNA silencing and quantified
differences in U87MG cell invasion. We confirmed effective siRNA knockdown by qPCR
(Figure 6E) and flow cytometry (Figure S5B), and observed no significant impact on cell
viability following knockdown (Figure 6F). siRNA or non-targeting siRNA treated cells
were seeded in transwell chambers, and the degree of cell invasion was evaluated as the
percentage of cells invaded compared to non-targeting siRNA treated cells. The resultant cell
invasion from three independent experiments is presented in Figure 6G. The silencing of
SLC16A1 and MRC2 caused 52.88% ± 9.70SEM, and 42.26% ±2.19SEM reduced cell
invasion respectively—similar to knockdown of the known invasion-mediating protein CD47
(57.74% ± 6.32SEM)-highlighting the role of these proteins in GBM invasion. We conclude
that a subset of TGF-β responders play a crucial role in the migration and invasion of GBM
cells, which in combination or alone may influence the clinical outcomes of GBM.

DISCUSSION

Author Manuscript

We formulated a systems strategy to develop GBMSig—a molecular signature for GBM
composed of protein targets (table S9) originating from the cell-surface of diseased cells that
provide excellent candidates that after shedding from the cell-surface can be detectable in
the blood. We reasoned that cell-surface proteins would be the best candidates as they are
most likely to be found in the blood due to their known role and function in disease
associated cell-signaling processes (Li et al., 2013). The heterogeneity of GBM is well
documented, and adds to the challenge of finding putative targets that can be reliably
detected across heterogeneous tumors. For this reason, we wanted to enrich for putative
targets that would likely be common to many GBM subtypes. Starting with four cell lines—
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two widely used cell lines of GBM, one established as having primary GBM cancer stem
cell properties (e.g. expression of CD133), and a healthy neural stem cell line—we
generated a list of putative targets by capturing and characterizing cell-surface proteins by
mass spectrometry. Identification of cell-surface proteins by biotin labeling helped to enrich
for proteins that are often difficult to detect because of their low abundance and
hydrophobicity. By requiring all candidates to possess a known transmembrane domain, we
likely eliminated many potential candidates. However, we feel our conservative approach
greatly lessened the possibility of false positives. While reducing our target number from
well over a thousand to 274, these targets were likely enriched for the properties most
central to GBM blood biomarkers. We could detect that ten of the fourteen targets in the
blood contained an N-terminal secretion signaling sequence (21 of 33 GBMSig targets)
consistent with the properties our experimental design targeted.
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We next relied upon existing microarray expression data to further enrich for candidate
targets and explored how well they might work as classifiers. With a number of regulatory
steps occurring between transcription and translation, we used the transcript array data as a
filter to identify targets with appreciable RNA expression. Because the REMBRANDT and
TCGA data sets were created for the purpose of better understanding heterogeneity across
GBM and other tumor types, their small control sample size is not ideal for identifying the
genes differentially expressed between tumor and normal samples. As we did not rely on the
microarray expression data for generation of targets, but rather as a filter for the elimination
of targets, the small control sample size was less of an issue. We further filtered our
candidate list by removing differentially expressed genes that were also found in
astrocytomas (148 samples) and oligodendrogliomas (67 samples), thus enhancing the
specificity for GBM. Additionally, this integrative analysis ensured that the classifier was
not based on expression of proteins that are the product of artifactual changes such as those
that arise from cell culturing. Utilization of laboratory grown cell lines for the generation of
candidates is consistent with the prior reports (Geiger et al., 2010). As GBM tumors are
typically more aggressive and metastatic than other brain tumors, this filtering step may have
selected for those genes specific to those functions. Previous work by our group used
microarray data alone to identify gene networks that differ across astrocytoma grades (Wang
et al., 2013). This previous work did not identify the TGF-β network and did not utilize
anything resembling the filtering and proteomic data integration presented here, highlighting
the differences achieved through an integrative omics approach. This filtering step may have
enabled the identification of several TGF-β network proteins. In doing so, we may also have
enriched for targets more likely to be in the blood, as metastatic mechanisms require
signaling external to the primary tumor. This is supported by our analysis of the survival
data, where co-expression of TGF-β responsive GBMSig genes correlated with poorer
outcome (p<0.003, Log Rank, Mantel-Cox) (Figure 6H).
Following this filtering, we utilized the REMBRANDT and TCGA data for evaluating the
performance of putative targets as classifiers. While the sensitivity (99.8%) and specificity
(80%) were encouraging, with an MCC value of 0.87, the small control sample size limits
the ability to determine the robustness of any classifier based on this evidence alone.
However, we performed end-to-end experimental verification of the classifier and
demonstrated that an integrated-omics approach was capable of producing a list of
Cell Syst. Author manuscript; available in PMC 2018 May 24.
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candidates that performed well as classifiers across platforms (proteomics, transcriptomics,
ELISA) and across experiments (REMBRANDT to TCGA).
With our GBMSig candidates that performed well as classifiers for both REMBRANDT and
TCGA, we turned to identifying those candidates that could best be quantitatively and
reproducibly detected in both tissue and blood. We were able to detect 14 of the 33 lowabundant proteins in the blood and 21 of the 33 in brain tissue using the recently developed
and sensitive approach of SRM. Further efforts to detect all proteins would likely have been
productive as absence of detection is just as likely to be due to technical as it is biological
reasons. Rather than optimize detection of all GBMSig targets, we chose to evaluate targets
that could be reliably detected via established ELISA assays—the gold standard of clinical
detection.
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The vast majority of published biomarker candidates have failed to make it to the clinic
(Micheel CM, 2012). A contributing factor to this high failure rate is the lack of properly
designed experiments that contain truly independent training and test sets. We were unable
to secure GBM and normal blood samples collected and processed by the same source. To
circumvent this limitation, we acquired samples from five different sources, distributing
samples from different sources into separate training and test sets. This approach makes it
improbable, though not impossible, that our high sensitivity and specificity are the result of a
batch effect. We have previously shown that multiple sources can be beneficial for the
purposes of robustness and have the ability to help mitigate batch effects (Ma et al., 2014;
Sung J, 2013; Wang et al., 2013). Even when mixing and matching samples in different
configurations, we found our test to be robust, with comparable sensitivity and specificity
(data not shown).
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Our integrated omics approach also produced a list of candidates that are related to known
characteristics of GBM. Many of the resulting targets had connections to TGF-β. We
investigated the role of SLC16A1 and MRC2 in TGF-β responsiveness, showing that
knockdown of these transcripts greatly reduced invasion. Recently, we have demonstrated
that HMOX1 expression is associated with GBM stemness and invasion (Ghosh et al.,
2016). MRC2 was previously shown to correlate with TGF-β1 expression in hepatocellular
carcinoma (Gai X, 2014). SLC16A1 has not previously been implicated in invasion nor
linked with TGFβ1 signaling. We have provided experimental evidence in favor of modular
roles for 17 GBMSig proteins (Table S10) in TGF-β signaling. How these proteins or other
proteins in our GBMSig connected to TGFβ1 signaling function in relationship to each other
is an outstanding question for future investigation.

Author Manuscript

Our ability to distinguish between blood from GBM patients and normal controls was
robust, with high sensitivity (95.2%) and specificity (95.2%). This resulted in an AUC of
0.99 for the training set and 0.98 for the validation set (Figure 5A–C), with great agreement
between the effect size (>|0.6|) and the sampling method (power>0.8) (Figure S3E).
Although we were not able to secure the control and the GBM samples from the same
source, a high AUC value was observed that was unexpected. It is possible that this high
agreement could be due to the novelty of the multi-omics, systems approach we used herein.
Further application and interpretation of the results in the context of other cancers and/or
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pathologies will be of interest moving forward. We attempted to demonstrate potential
clinical utility in assaying changes in the blood concentrations of 3 of 4 GBMSig proteins
following tumor resection (Figure 5D–E, S4A–B). Given the non-specificity of MRI
imaging in evaluating the effectiveness of therapeutic options, performance of GBMSig in
the longitudinal assessment of therapeutic changes might widen the scope for disease
management in the future.
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As our selection criteria for which targets to assay by ELISA were based on 1) SRM
detection in the blood; 2) high AUC values (>0.95) in ROC analyses of transcriptomic data
(Figure S2D–E); and 3) availability of commercial ELISA kits, we anticipate a canvasing of
other targets for which reliable ELISA data could be generated would increase the options
for development of a GBM-specific blood test—especially from the GBMSig extended
candidate list. Targets with smaller variance or greater separation between case and control
might also improve robustness or be the basis of distinguishing among diseases. Although
our candidate selection process was designed to increase the likelihood of robust separation
between GBM and lower grade brain tumors and healthy controls, performance of GBMSig
in separating non-GBM cancer such as liver cancer is also encouraging (Figure S2G).
However, it remains to be evaluated if other cancers or pathologies would exhibit similarities
and/or differences in the pattern of GBMSig expression.

Author Manuscript

We have demonstrated the power of integrating large-scale transcriptomics data together
with shotgun proteomics to identify proteins that can be quantitatively measured and used to
distinguish between the blood of a GBM patient and a healthy individual. The TGF-β
connection of several of our GBMSig targets lends itself to biological interpretation that is
often lacking with statistically heavy approaches. Arguably, this is a product of how we
integrated experimental proteomics data with carefully analyzed existing transcriptomics
data. Translating what we have learned here to a clinical application requires significantly
more work, but many of the principles and systems applications demonstrated here can
enable future efforts. We have an excellent candidate list of GBM biomarkers with which to
move forward into the validation stage. We believe this general approach will be applicable
to generating diagnostic blood protein panels for virtually any disease where the phenotype
distinctions between normal and disease are clear.

STAR*METHODS
Detailed methods are provided in the online version of this paper and include the followings:
Contact for Reagent and Resource Sharing

Author Manuscript

Further information and requests may be directed to Leroy Hood at the Institute for Systems
Biology (lhood@systemsbiology.org).
Experimental Model and Subject Details
Human Studies—IRB committee approvals and informed consent were obtained from all
patients. The inclusion criteria for GBM patients were: 1) diagnosed as GBM based on
clinical assessment, 2) plasma samples (collected in K2-EDTA tubes) were obtained prior to
surgical removal of tumor mass, 3) age was >15 yrs., 4) subject was not suffering from any
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other cancer, 5) GBM patients received standard care of treatment, 6) both male and female
subjects were included, 7) plasma samples were archived, labeled and fresh frozen. Age and
gender of the subjects are provided in table S7. Healthy controls were purchased from
Bioreclamation (Healthy-source-1 and Healthy-source-2A), and Proteogenex (Healthysource-2) with the following inclusion criteria 1) subjects were healthy with no known
chronic diseases, 2) no previous history of cancer, 3) age and gender matched with that of
GBM subjects, and 4) plasma samples were archived, labeled and fresh frozen. GBM
plasmas for the training set and longitudinal set (collected pre-operatively and postoperatively at 24hrs, 48hrs, and ~10 days) were collected from Swedish Medical Center,
Seattle, and the validation set were collected from California Pacific Medical Center
Research Institute (CPMCRI), San Francisco. Equal number of GBM (21 subjects) and
healthy (21 subjects) blood plasma specimens was selected for training data set. Power
analysis (>0.8) justified the inclusion of similar number of GBM (21 subjects) and healthy
(21 subjects) blood plasma samples for the validation set. For power analysis, please refer to
python codes in Data S1 and the figure S3E.
Cell Culture—The human GBM cell lines U87MG and T98 obtained from ATCC were
grown in DMEM high glucose culture medium supplemented with 10%FBS and Pen Strep.
Neural stem cells (NSCs) from Millipore and cancer stem cells (CSCs) from Celprogen were
grown according to suppliers’ specifications.
Methods Detail
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Cell-Surface Labeling and Mass Spectrometry—EZ-Link-Sulfo-NHS-SS-biotin
(Pierce) kit was used to surface label U87, T98, neural stem cell (Millipore) and cancer stem
cell (Celprogen) according to manufacturer instruction. Biotinylated cell surface proteins
were affinity-purified on neutravidin beads (supplied with the kit). After stripping off nonspecifically bound proteins by several rounds of washing with the lysis buffer (supplied with
the kit) followed by water wash (to remove excess reagents), labeled proteins were
selectively eluted with DTT at elevated temperature to ensure higher recovery of bound
proteins. Eluted proteins were concentrated onto 10kDa micro ultrafiltration unit and
reduced in the same ultrafiltration unit with 10mM TCEP for 60 min at 37°C. Excess TCEP
was neutralized by washing the membrane with equal volume of 100mM ammonium
bicarbonate followed by alkylation with 55mM iodoacetamide for 1hr in dark. Excess
alkylating agent was quenched with molar equivalent of TCEP by incubating at RT for
15min followed by washing the membrane several times with digestion buffer containing
50mM ammonium bicarbonate, 10% TFE and 1mM CaCl2. Proteins were digested on
membrane serially with trypsin for 12hrs at 37°C with 1:25 enzyme-to-protein ratio and Glu
C for 6 hrs with 1:50 enzyme-to-protein ratio at RT in dark, respectively. Enzymatic
digestion was quenched by adding 20μl of 0.2%FA, and digested materials were collected by
centrifugation. Peptides were lyophilized and re-dissolved in 1% ACN, 0.1% FA for mass
spec analysis using a Thermo Electron Orbitrap mass spectrometer (LTQ ORBITRAP)
equipped with an electrospray ionization source in line with an Agilent HP1100 liquid
chromatography system. Peptide digests were enriched onto a 2cm pre-column packed inhouse with 200Å Magic C18AQ resin and separated using a ProteoPep II 75μm i.d. × 10cm
analytical column on 160 min ACN gradient as follows: 2%B (Buffer B-100%ACN/
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0.1%FA) for 5min, 2–10%B for 20min, 10–25%B for 65min, 25–40%B for 20min, 40–
60%B for 15min, 60–100%B for 10min, and held at 100%B for 13 min followed by
equilibration of column for 17min with buffer A (Buffer A-2%ACN/0.1%FA). Pump flow
rate was maintained constantly at 0.350μl/min. Mass spectrometer was operated in positive
data-dependent acquisition mode with 1 S MS scan (m/z 300–1800; 30,000 resolution)
followed by 9 MS/MS events for peptides with charge states between +2 and +4. Dynamic
exclusion was set for 60 sec. Each isolate was run three times. After data acquisition,
Xcalibur (Thermo) raw data were converted to mzXML format using ReAdW profile and
default parameters. Peptide assignments were done using the GPM (www.thegpm.org).
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Brain Tissue Processing—Brain tissues were homogenized in tissue lysis buffer (TLB)
composed of 100mM n-octyl-glucoside, 1% NP-40, 150mM NaCl, 1mM PMSF, 2mM
sodium orthovanadate and 50mM sodium fluoride in 50mM TEAB, pH8.0. Tissue
homogenate was clarified by centrifugation at 10,000×g for 10 min and the supernatant
containing the proteins of interest was preserved at −80°C till further use. For SRM analysis,
tissues were reduced, alkylated, and then digested with trypsin and Glu C o/n in dark.
Digestion reaction was quenched with TFA, and peptides were lyophilized, C18 purified and
solubilized in 1%ACN/0.1% FA for SRM analysis.
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GBM Subtyping—Total RNA was isolated from tissue samples with Triazol, and then
cleaned with RNeasy MinElute Cleanup Kit. 1 μg of total RNA was used to generate 100 μl
of cDNA using the High Capacity cDNA Reverse Transcription Kit. Real-time PCR of
MGMT was performed on the ABI PRISM 7900 HT detection system using 33 Taqman
probes (Phillips et al., 2006) and Taqman reagents under default conditions: 95°C for 10
minutes, 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute with human betaglucuronidase (hGUS) as endogenous control. All assays were done in triplicate. The
expression level of each gene (Δct) for each tissue sample is calculated compared to the
hGUS expression level using the formula 2−(Ct value of gene − Ct value of hGUS). qRT-PCR was
performed for 4 GBM tissue samples (Table S5) for the 33 gene panel as described by
Phillips et al. For each gene we obtained the average Δct (μ) and standard deviation (σ). For
each tissue sample we calculate standard scores (z) for all 33 genes as follows: zg = Δctg −
μ/σg, where g ∈ 33 gene panel. Three components: 1) Mesenchymal (M), 2) Proliferative (P)
and 3) Proneuronal (N) expressions were calculated by taking the average of z scores of all
genes belonging to the corresponding component.
M = μ(zg), where g ∈ component Mesenchymal
P = μ(zg), where g ∈ component Proliferative
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N = μ(zg), where g ∈ component Proneuronal
Finally, the subtype is determined using the following reference range.
Mesenchymal M > P + 0.2, M > N + 0.2
Proliferative P > M + 0.2, P > N + 0.2
Proneuronal N > M + 0.2, N > P + 0.2
Prolifmes P > N + 0.2, M > N + 0.2, |P-M| < 0.2
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Mesneuronal M > P + 0.2, N > P + 0.2, |N-M| < 0.2
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Prolifneuronal P > M + 0.2, N > M + 0.2, |N-P| < 0.2
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SRM Assay Development and Analysis—Agilent Triple Quadrupole equipped with
ChipCube nanoelectrospray ionization source in line with 1200 nanoFlow HPLC system was
employed for SRM assay development and subsequent analysis. Cell surface peptide library
developed through prior high-resolution shotgun analysis (described earlier in shotgun mass
spectrometry section) provided the foundation to synthesize C-terminally labeled (13C15N)
surrogate peptides for 33 GBMSig. Collision energy (CE) values for each peptide bond were
optimized using the Mass Hunter Optimizer for Peptides Software (Agilent Technologies).
All combinations of +2, +3 and +4 of Q1 and +1 and +2 of Q3 ion pair (only y-series of
ions) of each peptide were undertaken for CE optimization. The top 4–5 transition pairs
(Q1/Q3) and corresponding CE values that ensured maximum signal intensity of SRM trace
was employed for quantitation. To develop dynamic-SRM (d-SRM) assay, retention time of
each peptide was determined a priori by spiking C-terminally labeled (13C15N) surrogate
peptides in presence of corresponding biological isolates (cell, tissue or serum). The
abundance of endogenous peptides was assessed from co-eluting surrogate peptides
(13C15N) which ensured precise quantification, All SRM acquisition method was run with
standard parameters viz. capillary voltage 1700–2100, a sheath gas flow of 11 L/min at a
temperature of 380°C, a drying gas flow of 15 L/min at a temp of 150°C, nebulizer gas flow
at 30psi, the fragmentor voltage at 380 V, the cell accelerator voltage at 7 V, an MS
operating pressure of 5×105 Torr and Q1/Q3 set to operate in unit resolution.
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All samples were loaded onto HPLC chip comprising of an enrichment column (160nL or
500nL) and a 150mm analytical C18 column. For plasma SRM analysis, 500nL enrichment
column was used and peptides were eluted (with nanopump flow of 0.3μl/min) over step
gradients as follows: 4%B for 2min, 25%B for 53min and maintained for 5min, 47%B for
12min and maintained for 10 min followed by column washing for 10 min at 0.5μl/min and
equilibration for 11min at 0.3μl/min flow rate.
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Plasma Depletion—All plasma samples were immunodepleted using a C10/10 column
packed in-house with 6ml bulk Seppro IgY14 matrix capable of depleting top 14 abundant
proteins from human plasma prior to SRM mass spectrometry. Flow through fraction was
concentrated onto 10kDa micro ultrafiltration unit and reduced in the same ultrafiltration
unit with 10mM TCEP for 60 min at 370C. Excess TCEP was neutralized by washing the
membrane with equal volume of 100mM ammonium bicarbonate followed by alkylation
with 55mM iodoacetamide for 1hr in dark. Excess alkylating agent was quenched with
molar equivalent of TCEP and incubating at RT for 15min followed by washing the
membrane several times with digestion buffer containing 50mM ammonium bicarbonate,
10% TFE and 1mM CaCl2. Proteins were digested on membrane serially with trypsin for
12hrs at 37°C with 1:25 enzyme-to-protein ratio and Glu C for 6 hrs with 1:50 enzyme-toprotein ratio at RT in dark respectively. Enzymatic digestion was quenched by adding 20μl
of 0.2%FA and digested materials were collected by centrifugation. Peptides were
lyophilized and re-dissolved in 1% ACN, 0.1% FA. After C18 clarification, each specimen
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was spiked with heavy (13C15N K/R) synthetic GBMSig peptides for SRM mass
spectrometry analysis.
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Flow Cytometry—The following antibodies were used in the study: SLC16A1, MRC2,
SLC16A3, CD47, and CD97. Cells were harvested after washing with ice-cold washing
buffer (PBS/0.1% sodium azide) and incubated with primary antibody in antibody
incubation buffer (1% BSA in PBS/0.1% sodium azide) for 1hr on ice. After washing the
cell pellets with washing buffer, cells were incubated with FITC conjugated anti-mouse or
PE conjugated anti-rabbit for 30 min on ice at 1:100 or 1:200 dilutions (prepared in antibody
incubation buffer) respectively. Unbound conjugates were removed by washing with the
washing buffer. Flow cytometry analysis was performed on FACSCalibur (BD Biosciences).
The mean fluorescence intensity (MFI) of FITC or PE-positive cells (three replicate runs)
was measured in comparison to respective isotype controls and the data were analyzed using
FlowJo.
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Western Blotting—Total proteins from U87 cells treated with TGF-β or its inhibitor were
lysed by sonication in TLB, composed of 100mM n-octyl-glucoside, 1% NP-40, 150mM
NaCl, 1mM PMSF, 2mM sodium orthovanadate and 50mM sodium fluoride in 50mM
TEAB, pH8.0. After protein estimation with Pierce 660, equal amount of protein (8μg) from
each isolate was separated by electrophoresis on Mini-Protean TGX 4–15% precast gel
(Biorad) and transferred to nitrocellulose membrane using a semi-dry blotting (Biorad)
apparatus. The membrane was blocked in TBS containing 3% FBS for 30min/RT and
incubated with anti-SMAD2 or C-terminally phosphorylated SMAD2 at 1:1,500 dilution or
anti-GAPDH at 1:15,000 dilution O/N at 40C. After washing the membrane with TBS/
0.1%T-20, membrane was incubated with appropriate HRP-conjugated secondary antibody.
The Fisher SuperSignal West Femto Chemiluminescent Substrate was used for detection.
The blot was visualized using Biorad gel documentation unit.
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siRNA Treatment and qPCR Analysis—U87 cells (one million) maintained in DMEM
high glucose culture medium supplemented with 10%FBS and penicillin-streptomycin were
plated in a 10 cm dish. 24 hours after seeding, cells were washed with HBSS prior to
reducing FBS to 0.2% in DMEM for siRNA treatment. ON-TARGETplus-SMARTpool
siRNAs for SLC16A1, MRC2, CD47 and ON TARGETplus Non-targeting pool were used
in the study. siRNAs were added at a 2:1 ratio of Dharmafect to siRNA for a final
concentration of 40 nM per the manufacturer instructions. For Quantitative Real-time PCR
(qRT-PCR) analysis of target gene inhibition, RNA was isolated per the manufacturer
instructions using Qiagen RNeasy Kit. RNA was converted to cDNA using Applied
Biosystems High Capacity cDNA Reverse Transcription Kit, per manufacturer instructions.
qRT-PCR was performed on an ABI 7900 HT 384-well format using Power Syber Green.
For the following genes, primers were designed using the online tools provided by
Integrated DNA technologies (IDT): HPRT1 forward 5′-TGCTGAGGATTTGGAAAGGG,
HPRT1 reverse 5′-ACAGAGGGCTACAATGTGATG, MRC2 forward 5′ACCAGCAACATATCCAAGCC, MRC2 reverse 5′-GAGTTTCCCTGGATGGTGTAG,
SLC16A1 forward 5′-GTGGCTTGATTGCAGCTTC, SLC16A1 reverse 5′TGGTCGCCTCTTGTAGAAATAC, CD47 forward 5′-
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TGGTATGGATGAGAAAACAATTGC, CD47 reverse 5′GTCACAATTAAACCAAGGCCAG. PCR pairs were designed to generate amplicons
between 90–130 base-pairs and pre-evaluated for a dissociation curve.
Cell Invasion Assay—Quantitative cell invasion assay was performed for U87MG cells
using the invasion kit according to manufacturer’s instructions. Percentage of siRNA treated
cells invaded in respect to non-targeting RNA treated cells were assessed from three
independent experiments with three replicates each time.
Quantification and Statistical Analysis
Data Normalization—All numerical raw data were normalized to standard score (Z-score)
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using the formula,
is the raw value and μ is the mean of the population, σ is the
standard deviation of the population.
SRM Quantification—SRM data were analyzed using Skyline (Bereman et al., 2012).
SRM traces were integrated by default peak integration method and processed with
Savitzky-Golay smoothing algorithm as described in Skyline. For precise identification and
quantification of targets, each SRM trace was manually inspected for three- Q1/Q3 transition
pairs with retention time determined empirically in prior runs. Peptide peak ratios
(endogenous: surrogate) from three independent runs of each sample were averaged and
expressed per μl of neat plasma or per μg of total protein as in the case of brain tissue
homogenates. Final data were expressed as standard score (Z score).
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Development of GBMSig—The human tissue expression array of GBM (N=228
subjects) and non-tumor (N=16 subjects) isolates in REMBRANDT [https://
gdoc.georgetown.edu/gdoc/] were used as training datasets to distinguish differentially
expressed cell-surface-transmembrane proteins as predicted using TMHMM algorithm
(http://www.cbs.dtu.dk/services/TMHMM/). We employed R: Bioconductor
(www.bioconductor.org) packages “affy” and “limma” for gene expression analysis. Cell
surface proteins differentially expressed between GBM and non-tumor with log2-fold
change >2X and FDR <0.05 was undertaken for further analysis. To identify GBM enriched
expression, astrocytoma (N=148 subjects) and oligodendroma (N=67 subjects) tissue arrays
in the same compendium were also assessed. Predictive accuracy of GBMSig was evaluated
using independent transcriptome dataset in TCGA (547 GBM tumors and 10 non-tumor
brain controls).
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Statistical Analysis and Modeling—True performance of GBMSig classifier was
evaluated through SVM. For SVM modeling, tissue transcriptomics data in REMBRANDT
were used as training set. Using R package CvTools, REMBRANDT data were splitted
(K=10) into training and validation sets. To achieve, the highest level of accuracy, we
performed autotuning of the hyperparameters and selected the best value for gamma and
cost for subsequent modeling as follows:
gamma

cost

error dispersion

1.00E–06

0.1

0.072727 0.05749596
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1.00E–05

0.1

0.072727 0.05749596

1.00E–04

0.1

0.072727 0.05749596

1.00E–03

0.1

0.072727 0.05749596

1.00E–02

0.1

0.072727 0.05749596

1.00E–01

0.1

0.072727 0.05749596

1.00E–06

1

0.072727 0.05749596

1.00E–05

1

0.072727 0.05749596

1.00E–04

1

0.072727 0.05749596

1.00E–03

1

0.072727 0.05749596

1.00E–02

1

0.072727 0.05749596

1.00E–01

1

0.022727 0.03214122

1.00E–06

10

0.072727 0.05749596

1.00E–05

10

0.072727 0.05749596

1.00E–04

10

0.072727 0.05749596

1.00E–03

10

0.068182 0.05769525

1.00E–02

10

0.013636 0.03067948

1.00E–01

10

0.009091 0.01916532

Best parameters: gamma=0.1 and cost=10.
SVM modeling was performed using the R package e1021. Minimization of the error
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, constraints=yi(wT
function was calculated using the following formula:
θ(xi)+b) ≥1− ζi and ζi ≥ 0, = 1, …. N;kernel θ=exp(−γ|xi−xj|; C=capacity constant, w=
vector of coefficients, b= constant, ζi= parameters for handling inseparable data, y= class
labels,xi=independent variables, and θ=kernel. To train the SVM model (C-classification)
we used radial kernel, gamma=0.1, and cost=10 (as determined following autotuning of the
hyperparameters). To assess the quality of the training results, accuracy of the model was
calculated from 100fold cross validation, which revealed mean accuracy of 98.63%. Once
the model was trained we evaluated the sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) of the classifier for independent validation set in
TCGA: Sensitivity= TP/|P|; Specificity= TN/|N|; Precision= TP/TP+FP; PPV= TP/(TP+FP);
NPV= TN/(TN+FN); where TP= True positive predicted by the model, |P|= Total Positive,
TN= True negative predicted by the model, |N|= Total Negative, FP= False positive i.e.
healthy instances predicted as GBM, FN= False negative i.e. true GBM instances predicted
as healthy.
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Power Analysis—To achieve empirical validity, power analysis was performed. Power
analysis of ELISA data were performed using statsmodel library in python with alpha=0.05;
effect size for ELISA data was calculated using Cohen’s d, where

For detailed analysis, please refer to the python code provided as Data S1.
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Linear Discriminant Analysis (LDA)—A LDA method was developed to evaluate the
performance of a subset of GBMSig (HMOX1, CD44, BIGH3, and VCAM1) proteins as
blood classifier. ELISA Training data set (GBM plasmas= 21, and Healthy plasmas= 21)
was modelled using LDA from the scikit-learn python package and the performance of the
classifier were predicted for the validation set (GBM plasmas= 21, and Healthy plasmas=
21). For detailed analysis, please refer to the python codes provided as Data S1.
Receiver Operating Characteristic (ROC) Curve Analysis—Diagnostic
performance and accuracy of the classifier in separating GBM and normal controls were
assessed through ROC analysis as described in Medcalc. Sensitivity and specificity for a
given GBMSig is calculated as: Sensitivity
and specificity
; where a=True
positive =(TP), b= False Negative (FN), c= False Positive (FP), and d= True Negative (TN).
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Data and Software Availability
Python code used in the study is provided as Data S1.
Proteomics data for individual cell lines and replicate analyses are available from
www.thegpm.org. Please refer to key resources table for unique GPM identification numbers
that are required to access the data.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
•

Cell-surface proteomics of four cell lines relevant in glioblastoma.

•

Development of a 33-cell-surface-protein signature for glioblastoma.

•

Association of a subset of the signature with TGF-β signaling and cancer
invasion.

•

Potential of a subset of GBMSig proteins as blood biomarkers.
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Description of the rationale and accompanying filtering steps applied to the initial list of
proteins identified through sulfo-NHS-SS-biotin tagging of intact cells from four cell lines:
U87MG, T98, CD133+ cancer stem cells and neural stem cells. From the 1480 candidate
proteins, 274 contained transmembrane domains. Corresponding probes were found for 202
targets in the REMBRANDT data set containing 228 GBM and 16 non-tumor brain tissue
specimens. Genes found to be commonly expressed in oligodendrogliomas and astrocytomas
were then removed to enrich for GBM-specific targets. This resulted in 33 targets identified
as GBMSig. SRM mass spectrometry assays were developed for each of these targets.
Twenty-one of the 33 GBMSig proteins could be detected across 4 GBM and 2 non-tumor
brain specimens. Fourteen of the 33 proteins were also detected in the blood (following
immunodepletion of the top 14 abundant blood proteins). Each of the 33 targets was
evaluated as a classifier on 547 GBM and 10 control samples from TCGA. Four targets were
selected based on the robustness as a classifier, ability to be detected in the blood and
availability of a commercial ELISA assay.
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Figure 2.
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Compositional analysis of cell-surface proteins (CSPs) from three independent runs by high
resolution mass spectrometry in (A) U87MG, (B) T98, (C) cancer stem cell (Celprogen),
and (D) neural stem cell (Millipore). Proteins with log(e)=−3 score (GPM) were considered
valid. Numerical data represents proteins identified in each isolates. E) Functional analyses
of cell-surface proteins with transmembrane domains identified in the study highlight the
enrichment of those biological processes that are known to be associated with cell-surface
activities. Fold enrichment is presented as a ratio of number of cell-surface transmembrane
proteins identified for a given biological process relative to whole genome annotations with
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indicated p values. F) Cartoon diagram (KEGG) showing the identification (highlighted in
orange) of those proteins associated with cell migration and invasion.
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Figure 3.
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Cell-surface proteins with transmembrane domains identified from shotgun proteomics were
evaluated for their differential expressions using transcriptome compendiums of
REMBRANDT and TCGA. A) The differential expression of 202 cell-surface
transmembrane proteins in GBM tissues (N=228) relative to non-tumor brain specimens
(N=16) of REMBRANDT transcriptome compendium. Expression values for these
transcripts were log2 transformed, and a minimum of two-fold average expression change
(FDR<0.05) between tumor and non-tumor brain tissues was used as cut-off for significance.
Clustering reflects the directionality of cell-surface transmembrane transcript expression
among GBM and controls. Non-tumor brain specimens are highlighted in yellow at the
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bottom. B) majority of the cell-surface proteins with transmembrane domains mapped to
REMBRANDT transcripts were discarded due to common expressions in non-GBM
diseases such as astrocytoma (N=148) and oligodendroma (N=67 tumors). Shown are 33
cell-surface transmembrane proteins that were subsequently tested for the development of
GBMSig classifier. Each column of the heatmap is presented as the average log2 [tumor/
non-tumor] ratios. CNT is non-tumor brain, AST is astrocytoma, and OLI is oligodendroma.
C) Principal component analysis (PCA) of REMBRANDT GBM transcriptome arrays with
GBMSig (n=33). Red dots represent non-tumor isolates and grey ones are GBM. Two
principal components can explain 43% of the variability. D) Principal component analysis
(PCA) of independent TCGA GBM transcriptome datasets composed of 547 GBM
specimens and 10 non-tumor brain controls with GBMSig (n=33). Two principal
components can explain 48% of the variability. Red dots represent non-tumor isolates and
grey ones are GBM. E) ROC analysis of REMBRANDT tissue arrays for individual
GBMSig proteins. Specificity (%) and Sensitivity (%) values of individual GBMSig were
plotted on X and Y axis respectively. Standard error of AUC was calculated using the
method described by DeLong et al. Orange color represents significance level P (Area=0.5)
<0.0001 while gray color represents P>0.01.Detailed analysis is provided in table S2. F)
ROC analysis of independent TCGA tissue arrays (GBM=547 subjects, NonTumor=10
subjects) for individual GBMSig proteins. Specificity (%) and Sensitivity (%) values of
individual GBMSig were plotted on X and Y axis respectively. Standard error of AUC was
calculated using the approach described by DeLong. The analysis revealed high degree of
specificities and sensitivities in discriminating GBM populations from controls with
significance level P (Area=0.5) <0.0001. Detailed analysis is provided in Table S2.
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Figure 4. Proteomic verification of GBMSig expression in GBM tissues by SRM mass
spectrometry
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A) Equal quantities of tissue homogenates from tumor (n=4) and non-tumor isolates (n=2)
were enzymatically digested, C18 clarified, and spiked with surrogate peptides labeled Cterminally with 13C15N K/R for SRM analysis. Ratios of endogenous and surrogate peptides
were centroided and presented as Z-score in the heatmap. A subset of GBMSig (*) was also
observed to be circulated in the blood plasma. Co-expression of several GBMSig proteins
with BIGH3 (TGFBI) - a known TGFβ-inducible protein might be indicative of the presence
of additional TGF-β responsive elements operating within GBMSig. Based on GBMSig
expressions, GBM and non-tumor tissues can be arranged into groups as revealed through
Spemann rank clustering. B) PCA analyses of GBMSig proteins as quantified by SRM mass
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spectrometry can distinguish GBM from non-tumor brain specimens with first two
components explaining 70.78% of variability, highlighting the robustness of GBMSig in
separating GBM from controls with high efficiency at both transcriptome and proteome
levels. C) Contributions of each GBMSig protein onto respective principal components.
Expected average contributions on PC1 and PC2 are denoted by a red and blue line
respectively. D) Subtyping of GBM 1–4 tissues were performed using qPCR for 33 genes as
described (Phillips et al., 2006). Accordingly, GBM-1 is assigned as prolifimes, GBM-2 as
mesenchymal, GBM-3 as proliferative, and GBM-4 as proneuronal. This subtyping allowed
us to explain the heterogeneities in GBMSig expression observed from proteomic analysis.
Subtype expression data (qPCR) are provided in table S5.
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Figure 5.
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Blood Diagnostic potentials of four GBMSig proteins. A) four GBMSig proteins viz. CD44,
VCAM1, HMOX1, and BIGH3 (TGFBI) were evaluated by ELISA assays using 84 plasma
samples obtained from 3 different locations. Despite different sites of collection, both
training set and validation set revealed statistically significant differences between GBM
(GBM-Src-1 and GBM-Src-2) and healthy controls(H-Src-1,H-Src-2, and H-Src-2A). p
values are two tailed and welch corrected. B) ELISA results from training set were modelled
using Linear Discriminant Analysis (LDA). The training set created a classifier with a
scaling factor of (0.72, −1.1, −.05. −.68) for HMOX1, BIGH3 (TGFBI), VCAM1 and CD44
respectively. The decision boundary coefficients are at (−1.83, 1.83) with an intercept of
−2.38. Performance of these four GBMSig proteins was assessed for an independent
validation set (GBM=21, Healthy=21). We observed 95.23% sensitivity and 95.2%
specificity with 95.2% accuracy for the independent validation set. Dec. Boundary is
Decision Boundary. C) Shown here is the ROC analysis of validation set that exhibited an
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AUC of 0.98, highlighting robust discerning ability of GBMSig proteins as attractive
candidates. D) MRI images showing the changes in tumor volume before (A) and after
resection (B) for ten GBM patients recruited prospectively for the blood analysis. E) Boxplot
showing the changes in the plasma values for 4 GBMSig proteins at 24hrs, 48hrs, and
10days (~) post-resection as measured through ELISA assays. Data were normalized to
preoperative condition for individual patient. Y-axis represents GBMSig values in ng/unit of
total protein. Black dots represent each patient and ‘*’ indicates p<0.05.
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Figure 6. Association of GBMSig proteins with TGF-β1 signaling network
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A) U87MG cells were treated with TGF-β1 or its inhibitor in presence or absence of FCS to
evaluate i) endogenous c-terminally phosphorylated SMAD2 (lane-1), ii) the ability of TGFβ1 to phosphorylate SMAD2 (lane-2), iii) the ability of TGF-β1-inhibitor to inhibit SMAD2
phosphorylation when cells were grown in normal media (lane-3), iv) the ability of TGF-β1
to induce SMAD2 phosphorylation in cells grown earlier in presence of TGF-β1-inhibitor
(lane-4), and v) the level of SMAD2 phosphorylation on prolong TGF-β1 exposure (50hrs)
when cells were grown in normal growth media (lane-5). The results demonstrated i) the
ability of TGF-β1-inhibitor in inhibiting c-terminal phosphorylation of SMAD2 (lane-3)
similar to when cells were grown in serum-free media (lane-1&2) and ii) reversible nature of
c-terminal phosphorylation inhibition of SMAD2 that could be reversed with TGF-β1
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treatment (lane-3&4). GAPDH was used as loading controls. B) SRM analysis of TGF-β or
its inhibitor treated U87MG cell lines revealed responsiveness of a subset of GBMSig
proteins towards TGF-β signaling. Complete list of GBMSig proteins detected in various
biospecimens and the responsiveness of these proteins towards TGF-β/Inhibitor is provided
in the supplementary tables S9 and S10 respectively. Data from four replicates SRM
analyses were centroided and presented as Z-score. C) flow cytometry analysis of a subset of
GBMSig proteins following TGFβ/Inhibitor treatment. Percentage of changes in mean
fluorescence intensity (MFI) was measured from treating U87MG cell lines with TGFβ
relative to its inhibitor. Data represent means ± S.D. from four-replicate analyses. D)
Network relationship (drawn using Cystoscape) between GBMSig proteins, which are
presented as nodes. These nodes are connected through edges based on known pathways and
co-expression. Color of the nodes is controlled by fold changes in expression of GBMSig
proteins on TGFβ treatment. Grey colored nodes represent extended relationship with
GBMSig proteins. E) qPCR analysis of siRNA mediated interference of a subset of TGFβ
responsive GBMSig elements viz. MRC2, SLC16A1, and CD47 genes in U87MG cells.
Results from three independent siRNA treatments (30hrs) were averaged (error bars
represent S.D.) and presented as CT ratios normalized to HPRT housekeeping gene. PARP1
expression was used as non-targeted control. F) Calcein AM assay indicates no significant
changes in cell growth and proliferation following siRNA mediated inhibition of SLC16A1,
MRC2, and CD47 in U87 cell lines. Data represent means ± S.D. from five replicate
analyses. G) siRNA treated U87 cells were allowed to migrate towards TGF-β1 gradient
through basement membrane (Cell Biolabs Inc.). Invaded cells were analyzed through
colorimetric assay. Results from three independent experiments were averaged and
normalized to non-targeting siRNA pools (scrambled). As evident, loss of cell migration
following siRNA mediated inhibition of SLC16A1 and MRC2 is similar to that of known
invasive marker CD47. Data represent means ± S.D. from three replicate analyses. H) A
panel of TGF-β responsive GBMSig (CA12, MRC2, TNC, CD44, SLC16A1, S100A10,
ITGA7, CLCCI, and SLC16A3) highlights poor survival (p<0.003, log rank, Mantel-Cox)
among GBM patients (class 2) when overexpressed relative to GBM patients where these
genes were low expressed (class 1).
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